arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Medline Inc.

MDLN

$34.30 ▼ -0.12 (-0.33%) at close

7 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Bearish

auto_awesome

Analytical Summary

Medline Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $29.4B

Dividend Yield —

Revenue Growth 11.6% ↗

Op. Margin 5.1% ↘

ROIC 1.0% ↘

FCF / Share $0.71 ↗

Trailing P/E 490.0x

Price / Book 2.5x

FCF Yield 2.1%

Debt / Equity 1.08

info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$7.68B

↑ +11.6% —

Net Income Profit after all expenses

$239.00M

↓ -25.1% —

Operating Margin Operating profit as % of sales

5.1%

↓ -10.5% 51th

FCF / Share Free cash flow per share

$0.71

↑ +82.8% —

Long-Term Debt Long-term obligations

$12.55B

— +0.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↑

Returns

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 2 metrics

Metric	Q2 FY2026 Jun 27, 2026 10-Q ↗	Q1 FY2026 Mar 28, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 28, 2025 10-Q ↗	Q1 FY2025 Mar 29, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Revenue Growth YoY (%)	11.6% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+45%)	10.7% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+33%)	—	—	—	—	—
Net Income Growth YoY (%)	-25.1% Weak Weak Year-over-year change in net income	-25.1% Weak Weak Year-over-year change in net income	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q2 FY2026 Jun 27, 2026 10-Q ↗	Q1 FY2026 Mar 28, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 28, 2025 10-Q ↗	Q1 FY2025 Mar 29, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Operating Margin (%) (%)	5.1% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-66%)	5.7% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-62%)	—	9.3% Caution Caution Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-38%)	8.6% Caution Caution Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-43%)	—	—
Effective Tax Rate (%) (%)	40.9% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	17.9% Good ↑ Good Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	7.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	4.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	3.1% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-74%)	3.3% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-73%)	—	4.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-61%)	4.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-60%)	—	—
FCF Margin (%) (%)	7.9% Caution ↑ Caution Improving Free cash flow as a percentage of revenue Optimal: > 10%	4.3% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	—	1.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	8.8% Caution Caution Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	2.53x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.32x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	—	0.27x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.83x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 27, 2026 10-Q ↗	Q1 FY2026 Mar 28, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 28, 2025 10-Q ↗	Q1 FY2025 Mar 29, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Return on Invested Capital (%)	1.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	1.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—
Return on Capital (%) (%)	1.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	1.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	2.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-86%)	2.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-86%)	—	—	—	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	Q2 FY2026 Jun 27, 2026 10-Q ↗	Q1 FY2026 Mar 28, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 28, 2025 10-Q ↗	Q1 FY2025 Mar 29, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Debt to Equity (x)	1.08x Caution → Caution Stable Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+81%)	1.11x Caution Caution Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+85%)	1.16x Caution Caution Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+94%)	—	—	—	—
Interest Coverage (x)	1.50x Caution ↓ Caution Declining Operating income divided by interest expense Optimal: > 5x	6.92x Good ↑ Good Improving Operating income divided by interest expense Optimal: > 5x	—	1.91x Caution Caution Operating income divided by interest expense Optimal: > 5x	4.20x Fair Fair Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$10.22B	$10.26B	$10.55B	—	—	$16.22B	—
Debt / EBITDA (x)	19.28x Weak Weak Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	18.49x Weak Weak Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Jun 27, 2026 10-Q ↗	Q1 FY2026 Mar 28, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 28, 2025 10-Q ↗	Q1 FY2025 Mar 29, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Revenue per Share (USD)	$8.97	$8.98	—	—	—	—	—
Basic EPS, GAAP (USD)	$0.07	$0.16	—	—	—	—	—
Free Cash Flow per Share (USD)	$0.71	$0.39	—	—	—	—	—
Book Value per Share (USD)	$13.51	$13.76	—	—	—	—	—
Tangible Book Value per Share (USD)	$-11.72	$-12.84	—	—	—	—	—
Basic Weighted Avg Shares (shares)	856.67M	819.08M	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q2 FY2026 Jun 27, 2026 10-Q ↗	Q1 FY2026 Mar 28, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 28, 2025 10-Q ↗	Q1 FY2025 Mar 29, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Working Capital (USD)	$9.03B	$8.64B	$8.19B	—	—	$5.83B	—
LT Debt (USD)	$12.55B	$12.49B	$12.48B	—	—	$16.42B	—
Total Equity (USD)	$11.57B	$11.27B	$10.74B	—	—	—	—

📋 What is driving earnings? 4 metrics

Metric	Q2 FY2026 Jun 27, 2026 10-Q ↗	Q1 FY2026 Mar 28, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 28, 2025 10-Q ↗	Q1 FY2025 Mar 29, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Sales/Revenue/Turnover (USD)	$7.68B	$7.35B	—	$6.89B	$6.64B	—	—
Depreciation Expense (USD)	$256.00M	$254.00M	—	$250.00M	$247.00M	—	—
Net Income, GAAP (USD)	$239.00M	$239.00M	—	$319.00M	$319.00M	—	—
Operating Cash Flow (USD)	$715.00M	$412.00M	—	$197.00M	$682.00M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 3 years · 7 quarters

Medline Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MDLN with peers